Chr amplification(1)(q21)

RMG is committed to provide robust high-quality real-world data. HDT/ASCT has been a well-established, efficient,and safe procedure and remains a standard of care for first-line treatment. Our analysis of 2149 newly diagnosed transplant-eligible pts confirms high effectiveness (mPFS 36 months) and out-standing safety (TRM 0,7%) of the procedure with long-term survival (mOS 97 months) for eligible NDMM pts.